Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 20/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162882 | 1.00 | CTSS (0.58) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL2162891 | 1.00 | CTSS (0.58) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL2163594 | 0.91 | CTSS (0.61) | CTSS | |
| SCHEMBL2163583 | 0.91 | CTSS (0.61) | CTSS | |
| SCHEMBL2163602 | 0.91 | CTSS (0.61) | CTSS | |
| SCHEMBL12196278 | 0.89 | CTSS (0.58) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL12196348 | 0.89 | CTSS (0.58) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL12196349 | 0.88 | CTSS (0.56) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL12196264 | 0.87 | CTSS (0.78) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL12196258 | 0.86 | CTSS (0.79) | CTSSCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | NOVARTIS AG | 2011-10-06 | — | — | US | claimed |
| US-7985749-B2 | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2011-07-26 | — | — | US | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| US-8268996-B2 | Compounds and compositions as cathepsin S inhibitors | IRM LLC (BM) | 2012-09-18 | — | — | US | disclosed |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | NOVARTIS AG | 2011-10-06 | — | — | US | disclosed |
| US-7985749-B2 | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2011-07-26 | — | — | US | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | CTSS 1/4885CYP3A4 1973/4885CYP2C9 1596/4885 |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | CTSS, CTSB, CTSF | CTSS 1/4885CYP3A4 1973/4885CYP2C9 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.